TAdd image
Tirzepatide
Weight LossSingleAlso known as: Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist showing greater weight loss than GLP-1 monotherapy in head-to-head trials.
Half-life
120 h
Common dose
2.5 – 15 mg
Dosing frequency
Weekly
Administration
Subcutaneous
How it works
Tirzepatide activates both GIP and GLP-1 receptors, producing complementary effects on insulin secretion, glucagon suppression, gastric emptying, and satiety. Clinical trials show 15–22% body-weight loss.
Protocol notes
Standard titration: 2.5 mg weekly for 4 weeks, increasing by 2.5 mg every 4 weeks up to 15 mg weekly. Slower titration improves GI tolerance.
Reported side effects
Nausea, diarrhea, vomiting, constipation, fatigue, injection-site reactions; risk of pancreatitis.